Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease.
Adult
Body Mass Index
Body Weight
Chromium Radioisotopes
/ chemistry
Cross-Over Studies
Diet, Fat-Restricted
Diet, Mediterranean
Edetic Acid
/ chemistry
Female
Humans
Intestinal Mucosa
/ metabolism
Male
Non-alcoholic Fatty Liver Disease
/ diet therapy
Overweight
/ diet therapy
Permeability
Prospective Studies
Treatment Outcome
Waist Circumference
Gut-liver axis
Liver steatosis
Nutrition
Personalized medicine
Visceral obesity
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
28 Jan 2019
28 Jan 2019
Historique:
received:
05
11
2018
revised:
14
01
2019
accepted:
18
01
2019
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
6
4
2019
Statut:
ppublish
Résumé
In non-alcoholic fatty liver disease (NAFLD), a high-fat or high-fructose diet increases intestinal permeability and promotes derangement of the gut-liver axis. We hypothesize that, diet could be able to modulate intestinal permeability in patients with NAFLD. To detect diet-induced modification of intestinal permeability in patients with NAFLD undergoing a Mediterranean diet or a low-fat diet. The current study was a dietary intervention for non-diabetic, patients with biopsy-verified NAFLD and increased transaminases. A crossover design was employed: participants underwent 16 weeks of Mediterranean diet, 16 wk of free wash-out, and 16 weeks of low-fat diet. Both diets were hypocaloric and no consumption of supplements was allowed. All patients were followed bimonthly by a dietitian. Evaluations of clinical and metabolic parameters were completed at baseline and at the end of each dietary period. Intestinal permeability was assessed by chromium-51 ethylene diamine tetraacetate excretion testing (51Cr-EDTA). Twenty Caucasian patients, 90% male, median age 43 years, body mass index (BMI) 30.9, with biopsy-verified NAFLD were enrolled. At the end of 16 weeks of a Mediterranean diet, a significant reduction in mean body weight (-5.3 ± 4.1 kg, Mediterranean diet is an effective strategy for treating overweight, visceral obesity and serum transaminase in patients with NAFLD. If the Mediterranean diet can improve intestinal permeability in patients with NAFLD, it deserves further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
In non-alcoholic fatty liver disease (NAFLD), a high-fat or high-fructose diet increases intestinal permeability and promotes derangement of the gut-liver axis. We hypothesize that, diet could be able to modulate intestinal permeability in patients with NAFLD.
AIM
OBJECTIVE
To detect diet-induced modification of intestinal permeability in patients with NAFLD undergoing a Mediterranean diet or a low-fat diet.
METHODS
METHODS
The current study was a dietary intervention for non-diabetic, patients with biopsy-verified NAFLD and increased transaminases. A crossover design was employed: participants underwent 16 weeks of Mediterranean diet, 16 wk of free wash-out, and 16 weeks of low-fat diet. Both diets were hypocaloric and no consumption of supplements was allowed. All patients were followed bimonthly by a dietitian. Evaluations of clinical and metabolic parameters were completed at baseline and at the end of each dietary period. Intestinal permeability was assessed by chromium-51 ethylene diamine tetraacetate excretion testing (51Cr-EDTA).
RESULTS
RESULTS
Twenty Caucasian patients, 90% male, median age 43 years, body mass index (BMI) 30.9, with biopsy-verified NAFLD were enrolled. At the end of 16 weeks of a Mediterranean diet, a significant reduction in mean body weight (-5.3 ± 4.1 kg,
CONCLUSION
CONCLUSIONS
Mediterranean diet is an effective strategy for treating overweight, visceral obesity and serum transaminase in patients with NAFLD. If the Mediterranean diet can improve intestinal permeability in patients with NAFLD, it deserves further investigation.
Identifiants
pubmed: 30700946
doi: 10.3748/wjg.v25.i4.509
pmc: PMC6350174
doi:
Substances chimiques
Chromium Radioisotopes
0
Edetic Acid
9G34HU7RV0
Chromium-51
9QAU17N705
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-520Déclaration de conflit d'intérêts
Conflict-of-interest statement: There are no conflicts of interest to report.
Références
Clin Lab. 2001;47(3-4):143-50
pubmed: 11294577
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Nucl Med Commun. 2001 Sep;22(9):997-1001
pubmed: 11505209
Ann Intern Med. 2002 Jul 2;137(1):1-10
pubmed: 12093239
N Engl J Med. 2003 May 22;348(21):2082-90
pubmed: 12761365
N Engl J Med. 2003 Jun 26;348(26):2595-6
pubmed: 12826632
N Engl J Med. 2003 Jun 26;348(26):2599-608
pubmed: 12826634
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Ann Thorac Surg. 2004 Feb;77(2):612-8
pubmed: 14759448
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Arch Intern Med. 2006 Feb 13;166(3):285-93
pubmed: 16476868
Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G518-25
pubmed: 17023554
Am J Clin Nutr. 2006 Oct;84(4):813-21
pubmed: 17023708
Diabetes Care. 2007 May;30(5):1075-80
pubmed: 17351275
Diabetes. 2008 Jun;57(6):1470-81
pubmed: 18305141
Diabetologia. 2008 Sep;51(9):1616-22
pubmed: 18597068
Nutr Res Rev. 2004 Jun;17(1):5-22
pubmed: 19079912
Gastroenterology. 2009 May;136(5):1552-60
pubmed: 19208352
Hepatology. 2009 Jun;49(6):1877-87
pubmed: 19291785
Gastroenterology. 2009 May;136(5):1490-2
pubmed: 19318102
Hepatology. 2009 Oct;50(4):1094-104
pubmed: 19637282
J Nutr Biochem. 2009 Sep;20(9):657-62
pubmed: 19679262
Hepatology. 2010 Jan;51(1):121-9
pubmed: 19827166
PLoS One. 2010 Aug 16;5(8):e12191
pubmed: 20808947
J Hepatol. 2012 Jan;56(1):255-66
pubmed: 21723839
J Hepatol. 2012 Apr;56(4):944-51
pubmed: 22023985
Gut. 2012 Apr;61(4):543-53
pubmed: 22110050
J Clin Gastroenterol. 2012 Jul;46(6):457-67
pubmed: 22469640
Curr Pharm Des. 2013;19(29):5314-24
pubmed: 23432669
J Hepatol. 2013 Jul;59(1):138-43
pubmed: 23485520
Am J Clin Nutr. 2013 Aug;98(2):349-57
pubmed: 23783298
Int J Hepatol. 2014;2014:560620
pubmed: 25328713
BMC Gastroenterol. 2014 Nov 18;14:189
pubmed: 25407511
Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):123
pubmed: 25645967
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5
pubmed: 25865049
Eur J Clin Nutr. 2015 Sep;69(9):1078
pubmed: 26014263
Clin Biochem. 2015 Sep;48(13-14):923-30
pubmed: 26151226
BMC Gastroenterol. 2016 Feb 02;16:14
pubmed: 26831892
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25
pubmed: 27273168
Liver Int. 2017 Jul;37(7):936-949
pubmed: 28371239
Eur J Clin Nutr. 2017 Dec;71(12):1455-1462
pubmed: 28537581
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Clin Nutr. 2018 Oct;37(5):1736-1743
pubmed: 28734553
Front Immunol. 2017 Sep 19;8:1159
pubmed: 28970836
Benef Microbes. 2018 Feb 27;9(2):199-208
pubmed: 29345158
Adv Nutr. 2018 Jan 1;9(1):30-40
pubmed: 29438460
J Hepatol. 2018 Jun;68(6):1239-1246
pubmed: 29571924
Hepatology. 2018 Nov;68(5):1741-1754
pubmed: 29729189
N Engl J Med. 2018 Jun 21;378(25):e34
pubmed: 29897866
Nutrients. 2018 Nov 18;10(11):null
pubmed: 30453660
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Acta Med Scand Suppl. 1966;460:1-392
pubmed: 5226858